Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases

This article was originally published here

In this regard, the companies will make use of GalXC, an RNA interference (RNAi) technology platform developed by Dicerna, for the discovery of new therapies. The collaboration will

The post Dicerna, Novo Nordisk sign RNAi deal for liver-related cardio-metabolic diseases appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply